NASDAQ:PPCB
Propanc Biopharma, Inc.
Propanc Biopharma, Inc. reported net income of −$18.9M in fiscal 2026. Free cash flow was −$5.7M, and the diluted share count rose 608.0%.Summary generated from Propanc Biopharma, Inc.'s SEC filings. Latest annual report filed Sep 25, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−161.9%
Debt / equityn/a
Free cash flow−$5.7M
FCF marginn/a
Share count change+608.0%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −2 | −2 | −2 | −57 | −18 |
| Net income | −3 | −3 | −2 | −59 | −19 |
| Free cash flow | n/a | n/a | n/a | n/a | −6 |
Recent filings
- S-1Registration statement
Oct 5, 2026 - 10-KAnnual report for the fiscal year ended Jun 30, 2026
Sep 25, 2026 - S-1Registration statement
Jul 17, 2026 - 8-KDirector or officer change
Jul 14, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026 - S-1Registration statement
Apr 10, 2026 - 8-KDirector or officer change
Feb 26, 2026 - 10-QQuarterly report for the period ended Dec 31, 2025
Feb 17, 2026